Journal article
Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
Abstract
This retrospective study aimed to investigate the safety profile of continuing or rechallenging patients with advanced cancer who developed grade≥2 immune-related adverse events (irAEs) on immunotherapy-based regimens. Our study had 25, 20, and 40 patients (N=85) in the Treatment Continuation (TCG), Non-Rechallenge (NRG), and Rechallenge Groups (RG), respectively. Subsequent irAEs recurrence were more common in RG than TCG and NRG (78% vs. 56% …
Authors
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Baetz T
Journal
Journal of Immunotherapy, Vol. 44, No. 1, pp. 41–48
Publisher
Wolters Kluwer
Publication Date
1 2021
DOI
10.1097/cji.0000000000000337
ISSN
1524-9557
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Adrenal Cortex HormonesAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug-Related Side Effects and Adverse ReactionsFemaleHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasmsPneumoniaRetrospective Studies